Blue Shield of California just negotiated a price of a blockbuster drug that is a quarter of what it pays now. Can it do the ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

A major California health insurer is set to offer one of the world’s top-selling drugs for free in a bid to show it can reach ...

AbbVie had promising double-digit growth in Skyrizi/Rinvoq and excellent ex-Humira portfolio sales growth. Read why ABBV ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

The Untitled Letter addresses a television advertisement for Ubrelvy that features Serena Williams. Among other issues cited ...

Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for ...

A roundup of current health news includes Johnson & Johnson's $2 billion investment in a new manufacturing facility, CVS ...

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early ...

The insurers are looking to disrupt Big Pharma's model of distributing drugs. One is even offering Humira biosimilars to ...

The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug ...